Why Neogen (NEOG) Stock Slumped Today

NEW YORK (TheStreet) -- Shares of Neogen Corp. (NEOG) closed lower by -4.32 to $36.97 on heavy trading volume on Tuesday afternoon, following the company's 2014 fourth quarter earnings results which didn't meet analyst expectations.

Neogen, an international food safety company, posted an increase in net income to $7.5 million, or 20 cents per share for the most recent quarter, compared to $7.0 million, or 19 cents per share for the same period last year.

Analysts polled by Thomson Reuters estimated the company would earn 21 cents per share.

Must Read: Warren Buffett's 25 Favorite Stocks


The company's net revenue was $67.26 million, up from $56.01 million for the 2013 fourth quarter.

Analysts expected revenue of $66.88 million for the quarter.

Separately, TheStreet Ratings team rates NEOGEN CORP as a Buy with a ratings score of B. TheStreet Ratings Team has this to say about their recommendation:

"We rate NEOGEN CORP (NEOG) a BUY. This is driven by multiple strengths, which we believe should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most stocks we cover. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity."

NEOG Chart NEOG data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

More from Markets

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing